|Positive WB detected in||HL-60 cells|
|Positive IHC detected in||human lymphoma tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
13588-1-AP targets Granzyme B in WB, IHC, IF, FC, ELISA applications and shows reactivity with human samples.
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Granzyme B fusion protein Ag3883|
|Full Name||granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)|
|Calculated molecular weight||247 aa, 28 kDa|
|Observed molecular weight||33 kDa|
|GenBank accession number||BC030195|
|Gene ID (NCBI)||3002|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
GZMB(Granzyme B) is also named as CGL1, CSPB, CTLA1, GRB and belongs to the Granzyme subfamily. This enzyme is necessary for target cell lysis in cell-mediated immune responses. The cytotoxic lymphocyte protease granzyme B (GzmB) can promote apoptosis through direct processing and activation of members of the caspase family. GzmB can also cleave the BH3-only protein, BID, to promote caspase-independent mitochondrial permeabilization (PMID:17283187). GzmB induces laminB degradation in isolated nuclei less efficiently than GzmA (PMID:11331782). This full length protein has 2 glycosylation sites and a signal peptide. Unglycosylated human granzyme B is 26 kDa and g high mannose glycosylated is 32 kDa and only 32kDa or smaller forms of granzyme B are accumulated within nuclei (PMID:8626751).
|Product Specific Protocols|
|WB protocol for Granzyme B antibody 13588-1-AP||Download protocol|
|IHC protocol for Granzyme B antibody 13588-1-AP||Download protocol|
|IF protocol for Granzyme B antibody 13588-1-AP||Download protocol|
|FC protocol for Granzyme B antibody 13588-1-AP||Download protocol|
|Click here to view our Standard Protocols|
J Am Acad Dermatol
Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
Toxicol Appl Pharmacol
Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice.
VEGF165b augments NK92 cytolytic activity against human K562 leukemia cells by upregulating the levels of perforin and granzyme B via the VEGR1-PLC pathway.
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Front Cell Infect Microbiol
The Role of Tim-3 on dNK Cells Dysfunction During Abnormal Pregnancy With Toxoplasma gondii Infection.